written on 08.05.2014

AstraZeneca’s Portfolio in Light of Pfizer’s $100bn Bid


Last week, Pfizer renewed its efforts to acquire UK pharma company AstraZeneca, reigniting its January 2014 offer of a record-breaking $98.9 billion. The January bid valued the company at GBP 46.61 per share, a 30% premium on AstraZeneca’s closing share price 2 days before the offer was first made. This week’s news sent the AstraZeneca […]